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Solid tumors are composed of tumor cells and stromal cells including lymphatic endothelial cells (LEC), which 
are mainly viewed as cells forming lymphatic vessels involved in the transport of metastatic and immune cells. 
We here reveal a new mechanism by which tumor exposed-LEC (teLEC) exert mitogenic effects on tumor cells. 
Our conclusions are supported by morphological and molecular changes induced in teLEC that in turn enhance 
cancer cell invasion in 3D cultures and tumor cell proliferation in vivo. The characterization of teLEC secretome 
by RNA-Sequencing and cytokine array revealed that interleukine-6 (IL6) is one of the most modulated molecules 
in teLEC, whose production was negligible in unexposed LEC. Notably, neutralizing anti-human IL6 antibody 
abrogated teLEC-mediated mitogenic effects in vivo, when LEC were mixed with tumor cells in the ear sponge 
assay. We here assign a novel function to teLEC that is beyond their role of lymphatic vessel formation. This work 
highlights a new paradigm, in which teLEC exert “fibroblast-like properties”, contribute in a paracrine manner to 
the control of tumor cell properties and are worth considering as key stromal determinant in future studies.   
1. Introduction 
The tumor microenvironment (TME) is a complex ecosystem con-
sisting of cancer cells, extracellular matrix and non-cancer stromal cells 
(immune, inflammatory, endothelial cells and fibroblasts) [1,2]. It is 
now well recognized that the complex crosstalk established between 
cancer cells and stromal cells actively contributes to tumor progression 
and metastatic dissemination that can occur through blood and/or 
lymphatic [3–5]. Lymphatic endothelial cells (LEC) lining initial capil-
laries are supported by a discontinuous basement membrane [6] and 
connected by “button-like” inter-endothelial adherens junctions formed, 
at least by homotopic interactions of vascular endothelial cadherin 
(VE-Cad). These specific discontinuous junctions could facilitate the 
uptake of interstitial fluid and (immune and cancer) cells, two key fea-
tures of initial lymphatic vessels (LV) [7]. 
Within the TME, LEC respond to growth factors (mainly vascular 
endothelial growth factors: VEGF-A/C) and contribute to an important 
LV remodeling and the formation of new LV from pre-existing ones [8]. 
This process of lymphangiogenesis correlates with lymph node (LN) 
metastasis and poorer clinical outcome [8–10]. After a long debate in 
the scientific community, experimental mouse model studies demon-
strated that metastatic cells in sentinel LN can further spread to distant 
organs by accessing specialized high endothelial venules (HEV) [11,12]. 
In addition to providing a route for tumor cell spreading, LV also in-
fluence anti-tumor immunity in primary tumor and in draining LN 
[13–15]. The complex interplay between LEC and the immune system in 
elaborating an immunosuppressive TME has recently emerged [14,16, 
17]. Advances in this field have highlighted LEC implication in immune 
cell recruitment/trafficking and in immunosuppression through 
different mechanisms that include, the production of PDL-1 promoting 
CD8+ T cell tolerization and indoleamine 2,3-dioxygenase (IDO) leading 
to tryptophane deletion and inhibition of T cell functions [13,15,18]. 
LEC appear increasingly as a heterogeneous cell population in terms of 
molecular and structural features, which display adaptive capacities 
[19,20]. The implication of LEC plasticity in the TME and how it could 
be involved during cancer progression and metastatic dissemination 
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Fig. 1. Direct contacts between LEC and tumor cells induce a disorganization of LEC monolayer (A) Schematic representation of LEC-tumor cell co-cultures. 
LEC monolayer were exposed or not to LEC (LEC-LEC culture) or to tumor cells (HaCaT series as indicated) (LEC-Tumor cell coculture). (B-C) Actin (B) and VE- 
cadherin (C) immunostainings of LEC monolayer co-cultured or not with LEC (LEC + LEC) or tumor cells (as indicated). Added cells were labeled either with a 
green (B) or a red (B) cell tracker. Nuclei were counterstained with DAPI (blue). (B) White asterisks correspond to gaps between cells. Bars = 200 μm and 100 μm in 
the left and right (higher magnification of the insert) images, respectively. (C) Arrow heads delineate the discontinuous staining of VE-cadherin at the LEC surface. 
White arrows delineate VE-cadherin internalization. Bars = 50 μm in the left panel and 25 μm in the right panel (higher magnification of the insert). (D) Quanti-
fication of gap density. The histogram is expressed as percentage (surface occupied by gaps divided by the total image surface). (E) Quantification of Dextran-FITC 
diffusion (in percentage) through a LEC monolayer challenged with LEC or tumor cells. (F) Analysis of LEC apoptosis by flow cytometry. The histogram shows the 
percentages of each LEC populations: healthy LEC (light grey), early apoptotic LEC (dark grey) and late apoptotic LEC (white). Results are expressed as mean ± SEM, 
and statistical analyses were performed using a Wilcoxon-Mann-Whitney test (*p < 0.05). Results are representative of at least three independent experiments. (For 
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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remains poorly documented [21,22]. In primary tumors, peritumoral LV 
are often enlarged and considered as the major route for dissemination. 
In the opposite, intratumoral LV appear collapsed due to the tumor 
pressure and are viewed as unfunctional and inconsequential in the TME 
[9,23–25]. These observations raise questions on LEC involvement in 
the evolution of TME during cancer progression. 
During the last decades, lymphatic research has mainly focused on 
molecular mechanisms driving lymphangiogenesis and how LV 
contribute to tumor and immune cell trafficking leading to an immu-
nosuppressive TME and metastatic colonization in LN in distant organs. 
LEC-derived chemokines drive tumor cell migration towards LV [26,27] 
and direct tumor cell-LEC contacts promote melanoma cell intravasation 
and invasion [28]. Tumor cells can also disrupt intercellular interactions 
between LEC forming gaps in the lymphatic wall that serve as entry sites 
for tumor cells in lymphatic vessels to reach lymph nodes [29–31]. This 
“vascular centric view” is neglecting putative roles of LEC in the TME 
that are far beyond their LV lining functions and pro-metastatic effects. 
We here speculate that LEC could exert other effects on tumor cells and 
tumor progression that are independent on their capacity to form a 
vascular wall. We hypothesized that LEC exposed to tumor cells (teLEC) 
can be stimulated to produce pro-tumorigenic factors and therefore be 
active stromal players in the complex TME. To address this issue, we 
used the HaCaT model of skin squamous cell carcinoma displaying 
features of tumor progression from benign (HaCaT cells) to low grade 
malignant (HaCaT–II–4 cells) and metastatic (HaCaT-A5-RT3 cells) tu-
mors [32,33]. The sensitivity of these cells to factors derived from 
activated stromal cells (fibroblasts) is well documented [34]. We 
demonstrate that tumor cells disrupt LEC monolayer integrity and 
induce a phenotypic switch in teLEC, which in turn promotes cancer cell 
proliferation and migration. Mechanistically, we provide in vivo evi-
dence that IL6-derived from teLEC promotes cancer cell proliferation 
index that is blocked by neutralizing anti-IL6 antibody. We are assigning 
a novel function to teLEC, which serve as a novel stromal source of 
regulators of tumor cell proliferation in the TME. 
2. Materials and methods 
2.1. Cells and reagents 
LEC are human dermal lymphatic microvascular endothelial cells 
purchased from Lonza (HMVEC-dLyAd, CC-2810, Verviers, Belgium). 
They were cultured in EGM2-MV medium (herein referred as complete 
medium) (CC-3202, Lonza) until confluence. Tumor cell lines used were 
derived from human skin carcinomas: (i) spontaneously immortalized 
human keratinocyte HaCaT cells, (ii) malignant keratinocyte 
HaCaT–II–4 cells, and (iii) metastatic keratinocyte HaCaT-A5-RT3 cells 
[32,33,35]. Tumor cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, 10938-025) complemented with 10% fetal bovine 
serum (10270-106), 1% glutamine (25030-123) and 1% pen-
icillin–streptomycin (15140-122) (all from Thermofisher, MA). 
Serum-starved tumor cells were treated with recombinant human IL6 
(I1395, Sigma, Belgium) and a neutralizing antibody against IL6 (2.5 
Fig. 2. LEC promotes tumor cell invasion in 3D cocultures. (A) Illustration of mono- and hetero-spheroids visualized by epifluorescence microscopy. LEC and 
tumor cells (HaCaT series as indicated) were stained by red and green cell trackers, respectively. Spheroids composed of green and red LEC were used as control. Bars 
= 100 μm. (B-C) Computerized quantifications of cell invasion represented as cell density (B) in a function of distance from the spheroid border (in mm), in which the 
blue curve corresponds to monospheroids while the red curve refers to heterospheroids, and the area under the curve (C). All results are representative of two 
independent experiments (spheroid number/experiment ≥ 14). Results are expressed as mean ± SEM, and statistical analyses were performed using a Wilcoxon- 
Mann-Whitney test (*p < 0.05; **p < 0.01; ***p < 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the Web 
version of this article.) 
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μg/ml, MAB 2061, R&D Systems, MN). LEC transfections with siRNAs 
targeting STAT1 (ON-TARGETplus Human STAT1 (6772), 
L-003543-00-0005, Dharmacon, Co, USA) or control siRNAs (ON-TAR-
GETplus Non-Targeting Pool, D-00180-10-05, Dharmacon) were per-
formed using Interferin (409-50, Polyplus). All cells used were negative 
for mycoplasma contamination. 
2.2. Confrontation of LEC monolayer to tumor cells 
The detailed protocol is available in the supplementary methods. 
2.3. Preparation of cell conditioned medium 
The detailed protocol is available in the supplementary methods. 
2.4. Measurement of apoptosis by Annexin V-violet/Propidium iodide 
analysis 
The detailed protocol is available in the supplementary methods. 
2.5. Cell proliferation assay 
The detailed protocol is available in the supplementary methods. 
2.6. Spheroid assay 
The detailed protocol is available in the supplementary methods. 
2.7. Immunofluorescence 
The detailed protocol is available in the supplementary methods. 
2.8. Permeability assay 
The detailed protocol is available in the supplementary methods. 
2.9. Western blotting 
The detailed protocol is available in the supplementary methods. 
2.10. RNA-sequencing and statistical analysis 
After RNA extraction (High Pure RNA Isolation Kit, 11828665001, 
Roche), bulk RNA-Sequencing was performed on an Illumina Next-
Seq500. The read length was 76 bps. The number of mapped reads per 
sample was between 19 and 23 million. The average coverage 
(sequencing depth) was estimated to be 10.8. 
The detailed protocol is available in the supplementary methods. 
2.11. Cytokine array and ELISA 
The detailed protocol is available in the supplementary methods. 
2.12. Mice 
Six-to seven-week-old Swiss Nude mice (620SWISSNUDE, Charles 
River, Ecully, France) were used throughout this study. The animals 
were maintained under a 12-h light-dark cycle with free access to food 
and water. Animal experiments were performed in compliance with the 
Animal Ethical Committee of the Liege University (Liege, Belgium) after 
the approval of the local Animal Ethical Committee. 
2.13. Ear sponge assay 
Gelatin sponges (Gelfoam, Pfizer, Ixelles, Belgium) were cut into 
small pieces (5 mm3) and incubated with cells as previously described 
[36]. Briefly, HaCaT-A5-RT3 or HaCaT–II–4 cells (2 × 106 cells per 
sponge) were added to gelatin sponge in the absence or presence of LEC 
(4 × 106 cell per sponge), in EBM2 serum-free medium. Human 
neutralizing anti-IL6 antibody (15 μg/ml, MAB2061, R&D Systems) or 
irrelevant mouse IgG2b antibody (15 μg/ml, MAB004, R&D Systems) (as 
negative control) was added to cell suspension. After 30 min of incu-
bation, sponges were embedded in interstitial type I collagen gel (1.5 
mg/ml, 41.254.02, Serva). Sponges were subcutaneously inserted into 
the ears of nude mice and left for 7 days [36,37]. Anti-IL6 or IgG2b 
antibody was injected directly in the sponge each day with a Hamilton 
syringe. At the end of the experiment, sponges were harvested, incu-
bated in 4% formol (11699408, VWR) for 4 h, dehydrated in ethanol and 
fixed in paraffin (X881.2, Leica). 
2.14. Immunohistochemistry 
The detailed protocol is available in the supplementary methods. 
2.15. Statistics 
Statistical analysis was performed using Prism 7 software (Graphpad 
Software, San Diego, CA, USA). Results were analyzed using the non- 
parametric Mann–Whitney test with two-tailed p value. P < 0.05 was 
considered as statistically significant. In histograms, mean ± SEM were 
represented. For proliferation assay, results are expressed as mean ±
SEM and Anova two-way significance test was used (*p < 0.05, ***p <
0.001). 
3. Results 
To study the reciprocal cross-talk between tumor cells and LEC, we 
used the HaCaT cell series characterized by a progression from benign to 
malignant and invasive tumor: immortalized keratinocytes (HaCaT), 
low-grade malignant keratinocytes (HaCaT–II–4) or high grade 
Fig. 3. LEC activated by tumor cells (teLEC) shift their transcriptomic and cytokinic profile. (A) Schematic representation of the experimental conditions. LEC 
were stimulated with conditioned medium (CM) of LEC themselves (Naive LEC) or of tumor cells (teLEC). Their RNA and conditioned media were subjected to RNA 
sequencing (B, C) and cytokine array (D, E). (B) Heatmap of the 38 most upregulated transcripts. The rows are ranked by log2FC decreasing order and the columns 
are the sample replicates. Each rectangle is scale-colored according to the read counts of the mapped gene (row) for the particular replicate (column). (C) Canonical 
pathways up-regulated (Ingenuity Pathway Analysis) with a positive z-score. (D) Cytokine array performed on LEC CM, HaCaT–II–4 CM, and teLEC CM. Rectangles 
represent cytokines enriched in teLEC CM. (E) Quantification of cytokine array spots representing levels of each cytokine in naive LEC CM (blue), HaCaT–II–4 CM 
(grey) and HaCaT–II–4 teLEC CM (pink). Graph is expressed as fold induction of secreted proteins (dot intensity compared to internal positive control). Rectangles 
represent cytokines enriched in teLEC CM and the dotted rectangle indicates the cytokine secreted by HaCaT–II–4 cells. (F) IL6 ELISA performed on CM of LEC or 
tumor cells in monoculture and on CM of teLEC (LEC stimulated by tumor cells as indicated). Graph represents the concentration (pg/ml) of human IL6. (G) LEC were 
stimulated by LEC CM or HaCaT series CM for the indicated time (minutes). STAT1 phosphorylation was evaluated by Western blot. (H) LEC were transfected with a 
siRNA targeting STAT1 or with a control siRNA (Ctr). Western blot analyses of STAT1 and GAPDH expression. (I) IL6 ELISA performed on CM of LEC or HaCaT–II–4 
CM after siRNA transfection. Results are expressed as mean ± SEM, and statistical analyses were performed using a Wilcoxon-Mann-Whitney test (*p < 0.05, **p <
0.01). All the results are representative of three independent experiments. (For interpretation of the references to color in this figure legend, the reader is referred to 
the Web version of this article.) 
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metastatic keratinocytes (HaCaT-A5-RT3) [35,38,39]. Human primary 
LEC (HMVEC-dLy) cultured with tumor cells or their conditioned me-
dium (CM) are referred herein as tumor exposed LEC: “teLEC”. We first 
determined the cellular changes induced by tumor cells on LEC prop-
erties (morphological changes in LEC monolayer), and vice versa by LEC 
on tumor cells (in vitro invasion). 
3.1. Tumor cells induce morphological changes in LEC and affect LEC 
monolayer integrity 
Since some tumor cells can induce LEC retraction forming gaps be-
tween cells [30,31], we first examined the impact of human skin car-
cinoma cells on LEC monolayer integrity (Fig. 1). LEC were cultured 
alone (LEC monolayer) or co-cultured with tumor cells labeled with a 
cell tracker (co-culture) (Fig. 1A). LEC addition to a LEC monolayer 
(LEC-LEC culture) was used as control to assess the specificity of the 
observed effects (Fig. 1A). The added LEC integrated into the monolayer 
without affecting its integrity (Fig. 1B and C). In sharp contrast, the 
HaCaT cell series induced gaps between LEC (Fig. 1B) and a disconti-
nuity in the endothelial-specific junctional protein VE-cadherin staining 
at the cell surface (Fig. 1C). A computerized method was set up to 
quantify gaps generated in LEC monolayer. The global gap density was 
3-fold higher when LEC were confronted to malignant HaCaT–II–4 cells 
and metastatic HaCaT-A5-RT3 cells than to immortalized HaCaT cells, 
which exerted a faint effect on LEC integrity (Fig. 1D). The tumor 
cell-induced disruption of LEC monolayer was further confirmed in a 
permeability assay (Fig. 1E). Dextran-FITC diffusion was enhanced by 
the addition of tumor cells, but not LEC on top of the endothelial barrier. 
FACS analyses revealed that LEC apoptosis was similar in all experi-
mental conditions (Fig. 1F). These data demonstrate that malignant 
keratinocytes induced the dissociation of LEC-LEC interactions without 
affecting cell viability. LEC are thus sensitive to malignant HaCaT cells 
that drastically impact their inter-cellular interactions. 
3.2. LEC promote tumor cell invasion in vitro 
A putative reciprocal effect of LEC on tumor cell properties was next 
investigated in spheroids embedded in a 3D collagen matrix (Fig. 2A–C). 
Spheroids were formed with a single cell type (monospheroids) or with 
two cell types stained with different cell trackers (green for LEC and red 
for tumor cells) (heterospheroids) (Fig. 2A). As control, spheroids 
formed of red and green stained LEC were used (homospheroids) to 
check that cell trackers did not influence cell behavior. In mono- and 
homo-spheroids, LEC displayed a capacity to sprout out and invade the 
collagen matrix (Fig. 2A). The distribution of tumor cell density around 
the spheroids was determined by using a computerized method of image 
analysis (Fig. 2B and C). When malignant (HaCaT–II–4) and metastatic 
(HaCaT-A5-RT3) tumor cells were mixed with LEC in heterospheroids, 
cancer cell migration was 2 to 3-fold enhanced as compared to that 
observed in monospheroids of tumor cells (Fig. 2A–C) (p < 0.01). In 
contrast, LEC only slightly affected the behavior of immortalized HaCaT 
cells (Fig. 2A–C) (p < 0.05). The apparently high migratory capacity of 
those cells could rely on their proliferative capacity. Tumor cells failed 
to affect LEC migration (SFig.1). These data point to the capacity of LEC 
to promote the invasiveness of malignant and metastatic tumor cells in a 
collagen matrix. They clearly provide evidence that these tumor cells are 
sensitive to factors produced by LEC. 
3.3. Tumor cells induce secretome changes in LEC 
To investigate the molecular mechanisms through which LEC influ-
ence tumor cell properties, we carried out a transcriptomic analysis 
through RNA-Sequencing on LEC cultured with control medium (“naive 
LEC”) or CM of tumor HaCaT–II–4 cells (“teLEC”) (Fig. 3A). This global 
transcriptomic analysis revealed 994 gene tags differentially expressed, 
with a log2FC ≥ 1, i.e. 491 upregulated and 503 downregulated in 
teLEC. The heatmap represents the 38 most up-regulated genes and 
ranked by decreasing Log2FC (Fig. 2B). Interleukin-6 (IL6) belongs to 
the ten most upregulated genes and shows an average fold change of 
57.3 (log2FC = 5.84) (Fig. 3B). Gene ontology and enrichment analysis 
was done with IPA and revealed up-regulated canonical pathways 
enriched in teLEC. Interestingly most of the pathways are associated to 
inflammatory response (Fig. 3C). 
CM of naive LEC, HaCaT–II–4 tumor cells or teLEC were next 
screened for a panel of cytokines/chemokines by using a cytokine array 
(Fig. 3D). In most cases, the resulting levels of secreted proteins reflected 
the production of tumor cells cultured alone. Interestingly, we noticed a 
huge production of IL6 in teLEC, while it was not detected in naive LEC 
and faintly produced by tumor cells (Fig. 3D and E). Specific ELISA were 
used to determine the exact protein concentrations in each experimental 
condition (Fig. 3F). The different HaCaT tumor cell CM secreted low 
amounts of IL6 (below 60 pg/ml). In contrast, a huge production of IL6 
was detected in teLEC activated by HaCaT–II–4 (392.8 ± 85.91 pg/ml) 
and HaCaT-A5-RT3 (273.2 ± 50.06 pg/ml) as compared to those acti-
vated by HaCaT cells (6.83 ± 5.49 pg/ml) or naive LEC (below detection 
threshold) (Fig. 3F). These data revealed a 5- to 6-fold enhancement of 
IL6 content in teLEC CM as compared to the sum of protein amounts in 
naive LEC CM and tumor cell CM. ICAM-1 production was also increased 
in teLEC activated by HaCaT–II–4 (1440 ± 211.4 pg/ml) and HaCaT-A5- 
RT3 (1225 ± 336 pg/ml), although to a lesser extend since ICAM-1 was 
produced both by naive LEC (395.8 ± 109.5 pg/ml) and tumor cells 
(145 ± 15.65 pg/ml for HaCaT–II–4 and 209.1 ± 24.76 pg/ml for 
HaCaT-A5-RT3) under basal conditions. The cytokine array analyses 
revealed the production of putative IL6 inducers in tumor cells: IFNγ, 
IL8, IL17, GM-CSF and MIP-1α/β, while TNFα, IL1 and IL4 were almost 
not detected at a protein level (Fig. 3e). To assess the putative role of 
tumor cell-derived cytokines on IL6 secretion, we evaluated, in LEC 
cultures, the phosphorylation status of STAT1 (Tyr 701), a downstream 
mediator of cytokines (Fig. 3g). When LEC were stimulated with CM of 
tumor cells, STAT1 phosphorylation was increased, with a pic at 15 min, 
suggesting its role in IL6 stimulation. In HaCaT–II–4 cells, STAT1 down- 
regulation by siRNA (Fig. 3h) partially reduced IL6 production (Fig. 3i). 
These data indicate that tumor-derived factors contributes, at least 
partially, to IL6 production by LEC via STAT1 activation. Several factors 
are likely implicated in the stimulation of IL6 production by LEC. 
3.4. LEC stimulate tumor cell growth in vivo 
IL6 is a pleiotropic cytokine that promote inflammation and tumor 
cell the proliferation. In line with a previous report [35], we confirmed 
that HaCaT-A5-RT3 proliferation was stimulated by recombinant IL6 
and blocked by a neutralizing anti-human IL6 (SFig.2). To determine 
teLEC impact on tumor cell growth in vivo, we confronted metastatic 
skin carcinoma cells (HaCaT-A5-RT3) and LEC in the ear sponge assay 
[36,37]. Gelatin sponges soaked with HaCaT-A5-RT3 with or without 
LEC were implanted in ears of nude mice (Fig. 4A). During 7 days, 
Fig. 4. teLEC-secreted IL6 enhanced HaCaT-A5-RT3 proliferation in vivo. (A) Schematic representation of the ear sponge assay using gelatin sponges soaked with 
human HaCaT-A5-RT3 with or without human LEC. (B) Human IL6 was targeted in the sponge by using a neutralizing antibody against human IL6, but not murine 
IL6. (C) Tumor cell proliferation was evaluated by HuNu (green) and hKi67 (red) co-immunostainings. Bars = 100 μm. (D) The presence of human LEC was assessed 
by double HuNu (red) and human podoplanin (green) staining. Blue corresponds to Dapi staining. Bars = 100 μm. (E) Histogram represents tumor cell proliferation 
(hKi67/HuNu density) assessed by a computer-assisted method (n ≥ 9). Results are expressed as mean ± SEM, and statistical analyses were performed using a 
Wilcoxon-Mann-Whitney test (***p < 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of 
this article.) 
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Fig. 5. teLEC-derived IL6 enhanced HaCaT-II-4 proliferation in vivo. (A) Tumor cell proliferation was determined as in Fig. 4. Bars = 100 μm. (B) The presence of 
human LEC was assessed by double HuNu (red) and human podoplanin (green) stainings. Blue corresponds to Dapi staining. Bars = 100 μm. (C) Histogram represents 
tumor cell proliferation (hKi67/HuNu density) (n ≥ 3). Results are expressed as mean ± SEM, and statistical analyses were performed using a Wilcoxon-Mann- 
Whitney test (*p < 0.05). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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sponges were daily injected with a control IgG antibody or a neutralizing 
antibody targeting human, but not murine IL6 (Fig. 4B). Tumor cell 
proliferation was assessed by double immunostaining using antibodies 
against human nuclei (HuNu) and human Ki67 (Fig. 4C). The presence of 
human LEC was checked by a double staining using anti-human podo-
planin and anti-HuNu (Figs. 4D and 5B). Notably, tumor cell exposition 
to LEC led to increased tumor cell proliferation, which was abrogated by 
anti-human IL6 (Fig. 4E). In line with IL6 pro-inflammatory effect, the 
neutralizing IL6 antibody reduced the inflammatory response as 
assessed by F4/80 macrophage staining (SFig. 3). Altogether, our data 
argue that LEC-derived IL6 promotes tumor growth. We next verified 
that the in vivo effects of LEC on tumor cell proliferation are not specific 
to metastatic HaCaT-A5-RT3 cells. Gelatin sponges soaked with 
HaCaT–II–4 cells with or without LEC were implanted in ears of nude 
mice (Fig. 5A). Interestingly, a LEC-derived IL6 stimulation of tumor cell 
proliferation was again observed and blocked by anti-IL6 antibody 
(Fig. 5C). 
4. Discussion 
It is now well recognized that LEC contribute to cancer progression as 
the structural component of lymphatic vessels [22]. Our investigation of 
the cross-talk established between cancer cells and LEC led to uncover a 
novel mechanism through which LEC exposed to tumor cells (teLEC) can 
directly regulate tumor growth. Mechanistically, we identify a recip-
rocal paracrine signaling pathway between tumor cells and LEC, in 
which IL6 production by teLEC exerts a protumorigenic effect. 
The innovative concept that LEC can exert pro-tumorigenic effects 
independent to their LV lining functions is supported by in vitro and in 
vivo data (Fig. 6). We provide evidence that in vitro, in a 3D-spheroid 
assay, LEC enhanced the invasion of malignant (HaCaT–II–4) and met-
astatic (HaCaT-A5-RT3) cells, but not that of immortalized HaCaT cells. 
We next took advantage of the original ear sponge assay [36] to expose 
HaCaT-A5-RT3 cells and HaCaT–II–4 to LEC in vivo. In this system, LEC 
and tumor cells were confined in a gelatin sponge surrounded by a 
collagen matrix to avoid cell scattering. We provide in vivo evidence that 
the direct exposition of LEC to tumor cells promotes tumor growth. 
Notably, the LEC-mediated mitogenic effect on tumor cells, was abro-
gated by neutralizing anti-IL6 antibody demonstrating a novel paracrine 
pathway between tumor cells and LEC. These original data underline the 
impact of LEC exposition to tumor cells, as well as the importance of the 
reciprocal cross-talk and cooperative interaction between LEC and 
tumor cells in cancer progression. 
IL6 is one of the major inflammatory interleukins that has been 
linked to cancer progression [35,40,41]. Through a cytokine array, IL6 
appeared as the most modulated soluble factor in teLEC. Interestingly, 
IL6 was produced at very low levels by tumor cells and almost not 
detected in CM of naive LEC. Significantly elevated IL6 concentration 
(>6-fold protein amounts) was detected in teLEC as compared to naive 
LEC. Importantly, IL6 contributes to a complex, reciprocally regulated 
cytokine network including IFNγ, IL8, GM-CSF, IL17 and MCP-1 [35]. 
We provide evidence that Stat1 activation contributes, at least partially 
to IL6 secretion by teLEC. It is likely that a cocktail of tumor-derived 
factors is involved in IL6 stimulation. The modulation of 
pro-inflammatory cytokine secretion observed in teLEC is in line with a 
recent study reporting a strong inflammatory gene expression signature 
in LEC isolated from murine mammary 4T1 tumors [21]. IL6 is released 
by various cells in the TME including cancer-associated fibroblasts 
(CAF). In pancreatic cancer, two distinct CAF subtypes have been 
characterized by either their myofibroblastic or inflammatory (IL6 
producer) phenotype [42,43]. The originality of our finding relies on the 
demonstration that LEC can serve as a key source of IL6 with 
pro-tumorigenic functions and reveals a new level of complexity to be 
considered in the TME. In the present study, we focused on IL6, being 
one of the most modulated molecules in teLEC, as a proof-of-principle. 
Given the importance of cancer-associated stromal cells, it is now 
worth revisiting how LEC contribute to cancer progression. This is of 
particular importance, as single cell sequencing data from different 
stromal cell types including endothelial cells [44] and CAF [42] are 
currently emerging and those analyses should not neglect LEC as a pu-
tative key contributor of TME and producer of pro-tumorigenic and 
pro-metastatic factors. Furthermore, the finding of pro-inflammatory 
Fig. 6. Graphical abstract of teLEC role in regulating tumor growth. LEC contribute to cancer progression as a structural component of lymphatic vessels (LV) 
that i) transport tumor antigens and immune cells (such as dendritic cells: DC) for immune surveillance (A); and ii) secrete cytokines (CCL19, CCL21 …) and cell 
adhesion molecules (ICAM, VCAM …) to attract and guide tumor cells towards LV for metastatic dissemination to lymph node (LN) (B). LEC exposed to tumor cells 
(teLEC) display morphological changes associated to cell retraction leading to gap formation in the lympho-endothelial wall that can offer entry site for tumor cells 
(C). In addition, teLEC produce pro-tumorigenic factors including at least IL6 that in turn promotes tumor growth (D). Such a reciprocal paracrine cross-talk between 
tumor cells and LEC highlight the capacities of LEC to exert “fibroblastic-like” (CAF-like) functions in the tumor microenvironment (D) that warrant to revisit the 
“vascular centric view” of LEC (A-C). 
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factor secretion by LEC in response to tumor cell-derived factors is of 
utmost interest since pro-inflammatory factors are able to enhance 
cancer progression and to favor resistance to treatment [45]. 
LEC have been reported to contribute to cancer progression through 
several mechanisms including lymphangiogenesis and the chemo-
attraction of tumor cells through the secretion of chemokines that guide 
tumor cells towards lymphatic vessels (Fig. 6). Tumor cells can induce 
LEC retraction and generate gaps in the lymphendothelial wall that 
serve as entry gates to the lymphatic vasculature [29]. These data are in 
line with the morphological changes (weakened intercellular junctions) 
observed in LEC monolayer exposed to the HaCaT cell series used here. 
The modulation of cell adhesion molecules in LEC exposed to tumor cells 
such as ICAM-1 [46,47] and VCAM-1 [21] can also contribute to tumor 
cell intravasation [21,48] (Fig. 6). Accordingly, we found enhanced 
ICAM-1 production in teLEC. The increased expression of VCAM-1 in 
cancer-associated lymphatic vessels has been recently reported to pro-
mote lymphatic permeability by weakening lymphatic junctions [21, 
49]. In addition to those effects on tumor cell intravasation into lym-
phatics, LEC have attracted substantial attention in their capacity to 
modulate the immune response [16,50,51] (Fig. 6). Our exciting dis-
covery that teLEC can directly influence proliferative and invasive ca-
pabilities of cancer cells reveals a new dimension of the reciprocal 
cross-talk between tumor cells and LEC. We show that the role of LEC 
in cancer extends beyond the formation of lymphatic vessels providing a 
route for metastatic dissemination and contributing to the immune 
response. 
Although the diversity in the developmental origins of lymphatic 
vessels together with as well as heterogeneity and multifunctional fea-
tures of LEC are emerging in physiological conditions [19,20], LEC 
plasticity in pathological conditions is less documented. Our work 
highlights a new paradigm, in which LEC exposed to tumor cells are 
subjected to morphological and molecular changes that directly influ-
ence tumor cell behavior and contribute to cancer progression. We 
propose that LEC should be considered as important stromal cells in the 
TME that can have additional roles independent of their LV lining 
functions. They can act as “CAF-like cells” by secreting tumor-promoting 
factors and are worth in-depth investigating in future research. 
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